The DISTINCT Trial Personalized Thrombosis Prevention Compared to Standard Care After Total Hip or Knee Replacement Surgery
Led by Leiden University Medical Center · Updated on 2026-09-08
10078
Participants Needed
13
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate individualized thrombosis prevention after total hip or knee replacement surgery. Despite standard blood thinner treatment given to all patients to prevent venous thromboembolism VTE, some still develop clots while others experience bleeding. The study investigates whether customizing the type and duration of blood thinner treatment based on each patients medical history can reduce both clotting and bleeding risks compared to the standard uniform approach.
Participants are grouped by their predicted VTE risk using the TRiPplasty score into low, intermediate, or high risk. Low-risk patients are randomized to receive either standard prophylaxis or a shortened treatment only during hospital stay. High-risk patients are randomized to receive standard treatment or a higher dose for six weeks. Intermediate-risk patients are observed without treatment changes. Blood thinners used include types of LMWH or DOACs given according to local standards, with dosing timing specified after surgery.
Participants complete four questionnaires one before surgery and follow-ups at 2 weeks, 6 weeks, and 3 months post-surgery to report any VTE or bleeding events. An additional questionnaire is sent one year after surgery if certain complications occurred, assessing quality of life and joint function. No extra hospital visits are required. The main outcomes measured are symptomatic VTE and major bleeding within 90 days post-surgery, along with other health and quality of life measures up to one year.
CONDITIONS
Brief Title
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
Research Team
B
Banne Nemeth, dr
R
Ruben Y Kok, drs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Scheduled to undergo an elective total hip arthroplasty or total knee arthroplasty
Aged 18 years or older
You will not qualify if you...
Primary arthroplasty for fractures
Revision surgery
Hemiarthroplasty
Pregnancy
Current use of therapeutic anticoagulant therapy (e.g., LMWH, DOAC, vitamin K antagonist)
Contraindication for study drugs
Insufficient Dutch language proficiency
Insufficient mental or physical ability to meet trial requirements
Active malignancy within six months before surgery (excluding certain skin cancers)
Use of thrombocyte aggregation inhibitors that cannot be stopped temporarily
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 6 weeks
Participants receive blood thinner treatment according to their risk group. Low-risk patients may get treatment only during hospital stay; high-risk patients may receive a higher dose for six weeks; intermediate-risk patients are observed without treatment changes.
Questionnaires before surgery and at 2 weeks, 6 weeks, and 3 months after surgery
Follow-up
Duration - Up to 1 year post-surgery
Participants complete an additional questionnaire at 1 year after surgery if they experienced certain complications, focusing on quality of life and joint function.
1 questionnaire at 1 year post-surgery
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
5
Similar Trials
Multi-center Study Collecting Ultrasound Images of Patients Suspected of Deep Vein Thrombosis for AI Model Training
Study of Home-Based Exercise Effects on Mobility After Pulmonary Embolism
Phase 2 Study Comparing Three Doses of SRSD107 to Enoxaparin for Safety and Effectiveness in Adults Aged 60 to 80 Undergoing Primary Unilateral Total Knee Replacement
Acutelines Biobank to Improve Early Detection and Personalized Treatment of Acute Diseases
Tracking Patient Outcomes from Emergency Admissions
Study of Combined Anticoagulant and Antiplatelet Treatment After Iliac Vein Stenting for Deep Vein Thrombosis
Feasibility and Safety of Dose-Adjusted Apixaban for Treating Cancer-Associated Blood Clots and Low Platelet Counts
Study Comparing Apixaban Pill Versus Enoxaparin Shot to Prevent Blood Clots After Head and Neck Cancer Surgery
Long-Term Evaluation of Aspiration Thrombectomy Using Symphony and Prodigy Systems for Arterial, Venous, and Pulmonary Blood Clots
Studying the Link Between Anti-factor Xa Activity and Blood Clots in Critically Ill ICU Patients
ARTS Trial Comparing Apixaban Versus No Anticoagulant in Adults Undergoing Abdominal, Gynecologic, or Urologic Surgery to Prevent Blood Clots and Bleeding
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Study protocol for the DISTINCT trial: inDividual, targeted thrombosIS prophylaxis versus the standard 'one-size-fits-all' approach in patients undergoing Total hIp or total kNee replaCemenT - a national, multicentre, randomised, multiarm, open-label trial.
Ruben Y Kok, Leti van Bodegom-Vos, Harmen B Ettema...
Development and validation of a clinical prediction model for 90-day venous thromboembolism risk following total hip and total knee arthroplasty: a multinational study.